Cesini L, et al. - Cyclophosphamide addition was evaluated in relapsed-refractory multiple myeloma patients (RRMM) who experienced biochemical relapse or progression without CRAB, during treatment with lenalidomide and dexamethasone (Rd), to slow down the progression in active relapse. Analysis revealed delayed progression in association with cyclophosphamide in 31 patients with RRMM treated with Rd who received cyclophosphamide (CRd) at biochemical relapse. They obtained favorable response rate and duration of PFS with minimal toxicities and low costs in relation to the addition of cyclophosphamide.